GlassScriptPhysician profile
Christopher R Chan
NPI 1790037356
$24,324.16
in general payments reported to CMS, 2019-2025
14 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,988 · 2022: $2,961 · 2023: $7,098 · 2024: $5,857 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,544 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,559 · Food and Beverage: $2,418 · Travel and Lodging: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,544.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,558.75 |
| Food and Beverage | $2,417.89 |
| Travel and Lodging | $854.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $6,001.78 | 2021-2025 | Novoseven, Novoeight, Rebinyn |
| Genzyme Corporation | $5,784.67 | 2023-2025 | |
| Csl Behring | $4,142.25 | 2021-2025 | Hemgenix, Idelvion, Afstyla |
| Genentech USA, INC. | $4,072.26 | 2021-2025 | Hemlibra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,929.02 | 2021-2025 | Vonvendi, Advate |
| Pfizer INC. | $1,337.60 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $433.50 | 2021-2025 | Kovaltry, Jivi |
| Genentech, INC. | $197.29 | 2024-2025 | Hemlibra |
| Octapharma USA, INC. | $161.04 | 2021-2024 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
| Biomarin Pharmaceutical INC. | $98.01 | 2024-2025 | Roctavian |
| Hema Biologics, LLC | $62.03 | 2024-2025 | Sevenfact, Sevenfact |
| Kedrion Biopharma, INC. | $60.62 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Masimo Corporation | $24.66 | 2022 | |
| Grifols USA, LLC | $19.43 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.